| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038080083 |
| P356 | DOI | 10.1038/NBT.1622 |
| P698 | PubMed publication ID | 20458316 |
| P5875 | ResearchGate publication ID | 44588130 |
| P50 | author | Elias Perentes | Q117834378 |
| Daniel Robert Roth | Q117834379 | ||
| P2093 | author name string | Frank Staedtler | |
| Olivier Grenet | |||
| Daniel Wahl | |||
| Frank Dieterle | |||
| Peter End | |||
| François Legay | |||
| André Cordier | |||
| Andreas Mahl | |||
| Gérard Maurer | |||
| Jacky Vonderscher | |||
| Pablo Verdes | |||
| Salah-Dine Chibout | |||
| Pierre Moulin | |||
| David Laurie | |||
| Serafino Pantano | |||
| Kevin Carl | |||
| P2860 | cites work | Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis | Q28216384 |
| Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries | Q28566878 | ||
| Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro | Q29347021 | ||
| The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 | ||
| Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 | ||
| ROCR: visualizing classifier performance in R | Q29615821 | ||
| Urinary cystatin C as a specific marker of tubular dysfunction | Q33235582 | ||
| Biomarkers of nephrotoxic acute kidney injury | Q33687717 | ||
| Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. | Q33913977 | ||
| Biochemistry and clinical role of human cystatin C. | Q34377103 | ||
| Translational toxicology and the work of the predictive safety testing consortium | Q34926489 | ||
| Pathophysiology of proteinuria | Q35083600 | ||
| Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin | Q35542081 | ||
| Update on cystatin C: new insights into the importance of mild kidney dysfunction | Q36446075 | ||
| The podocyte's response to injury: role in proteinuria and glomerulosclerosis | Q36474870 | ||
| Monitoring kidney safety in drug development: emerging technologies and their implications. | Q37050523 | ||
| Early detection of acute kidney injury: emerging new biomarkers. | Q37084913 | ||
| New biomarkers of acute kidney injury | Q37125704 | ||
| Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. | Q38289995 | ||
| Acute kidney injury, mortality, length of stay, and costs in hospitalized patients | Q39730814 | ||
| Clusterin: Physiologic and pathophysiologic considerations | Q40467340 | ||
| Next-generation biomarkers for detecting kidney toxicity | Q42589715 | ||
| Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury | Q43067029 | ||
| Early detection of acute renal failure by serum cystatin C. | Q45028930 | ||
| Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam | Q46593011 | ||
| Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats | Q46872360 | ||
| Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. | Q51913525 | ||
| Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. | Q51935158 | ||
| Intrarenal distribution of clusterin following reduction of renal mass | Q57741441 | ||
| Depletion of clusterin in renal diseases causing nephrotic syndrome | Q57980392 | ||
| Towards consensus practices to qualify safety biomarkers for use in early drug development | Q58071230 | ||
| Direct radioimmunoassay of rat cystatin C: increased urinary excretion of this cysteine proteases inhibitor during chromate nephropathy | Q68803304 | ||
| Effects of gentamicin on the renal uptake of endogenous and exogenous protein in conscious rats | Q68886903 | ||
| Renal handling of radiolabelled human cystatin C in the rat | Q71682614 | ||
| Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies | Q72024916 | ||
| Clusterin and the kidney | Q72145500 | ||
| Urinary alanine aminopeptidase and β2-microglobulin as measurements of aminoglycoside-associated renal impairment | Q72575452 | ||
| The significance of beta-2 microglobulinuria associated with gentamicin therapy | Q72655975 | ||
| Induction of clusterin in tubules of nephrotic rats | Q74080456 | ||
| Serum cystatin C as a marker of glomerular filtration rate | Q79279423 | ||
| Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity | Q80206977 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 463-469 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury | |
| P478 | volume | 28 |
| Q64889997 | A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury. |
| Q43067026 | A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function |
| Q84199362 | A roadmap for biomarker qualification |
| Q36223352 | Ambient Melamine Exposure and Urinary Biomarkers of Early Renal Injury. |
| Q34749242 | An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors |
| Q37583628 | Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration |
| Q38363848 | Arsenic-mediated nephrotoxicity |
| Q89731349 | Association Between Cystatin C and Cardiac Function and Long-Term Prognosis in Patients with Chronic Heart Failure |
| Q59353706 | Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals following Tenofovir Disoproxil Fumarate Initiation |
| Q33905075 | Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. |
| Q34039254 | Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology |
| Q59008042 | Biomarkers for kidney damage should speed drug development |
| Q38015939 | Biomarkers for monitoring therapeutic side effects or various supratherapeutic confounders after kidney transplantation |
| Q37225333 | Biomarkers for renal transplantation: where are we? |
| Q37893446 | Biomarkers in chronic kidney disease: a review |
| Q92442653 | Biomarkers of Drug-Induced Kidney Toxicity |
| Q41817067 | Biomarkers of acute kidney injury |
| Q34149513 | Biomarkers of collecting duct injury in Han-Wistar and Sprague-Dawley rats treated with N-phenylanthranilic Acid |
| Q38628143 | Biomarkers of drug-induced acute kidney injury in the adult. |
| Q34814081 | Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions |
| Q38622968 | Building a roadmap to biomarker qualification: challenges and opportunities |
| Q39604668 | Camelid genomes reveal evolution and adaptation to desert environments |
| Q38266417 | Cell- and biomarker-based assays for predicting nephrotoxicity |
| Q38271314 | Challenges facing early detection of acute kidney injury in the critically ill. |
| Q37591910 | Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers |
| Q38477379 | Characterization of the canine urinary proteome |
| Q37900798 | Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). |
| Q38111809 | Clinical use of biomarkers for toxicant-induced acute kidney injury |
| Q35720816 | Clusterin attenuates the development of renal fibrosis |
| Q93110539 | Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury |
| Q48357429 | Comparative study of radioprotective effects of selenium nanoparticles and sodium selenite in irradiation-induced nephropathy of mice model |
| Q43683587 | Comparison between male and female Sprague-Dawley rats in the response of urinary biomarkers to injury induced by gentamicin |
| Q41610027 | Comparison of changes in urinary and blood levels of biomarkers associated with proximal tubular injury in rat models |
| Q41678935 | Comparison of diglycolic acid exposure to human proximal tubule cells in vitro and rat kidneys in vivo |
| Q44247330 | Comparison of the MesoScale Discovery and Luminex multiplex platforms for measurement of urinary biomarkers in a cisplatin rat kidney injury model |
| Q34033853 | Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury |
| Q36564103 | Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate. |
| Q42287291 | Correlation of histopathology, urinary biomarkers, and gene expression responses following hexachloro-1:3-butadiene-induced acute nephrotoxicity in male Hanover Wistar rats: a 28-day time course study. |
| Q39523252 | Current challenges and controversies in drug-induced liver injury. |
| Q37782230 | Cystatin C in acute kidney injury |
| Q47557419 | Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer's Biomarker |
| Q55260734 | Dietary Cadmium Intake and Its Effects on Kidneys. |
| Q34658957 | Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache |
| Q37942277 | Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury |
| Q42353448 | Early kidney damage induced by subchronic exposure to PM2.5 in rats. |
| Q33421669 | Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. |
| Q92029125 | Effects of Dexmedetomidine on the RhoA /ROCK/ Nox4 Signaling Pathway in Renal Fibrosis of Diabetic Rats |
| Q45838381 | Enrichment of cells with TALEN-induced mutations using surrogate reporters |
| Q88675491 | Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification |
| Q37287667 | Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats |
| Q42917815 | Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity |
| Q41359427 | Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells |
| Q28385546 | Evaluation of cystatin C as an early biomarker of cadmium nephrotoxicity in the rat |
| Q34267508 | Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials |
| Q60044544 | Evaluation of the potential nephrotoxicity and mechanism in rats after long-term exposure to the traditional Tibetan medicine tsothel |
| Q36204158 | Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury |
| Q28573774 | Fibrinogen β-derived Bβ(15-42) peptide protects against kidney ischemia/reperfusion injury |
| Q60310411 | Gentamicin induced acute renal damage and its evaluation using urinary biomarkers in rats |
| Q99350177 | Glomerular clusterin expression is increased in diabetic nephropathy and protects against oxidative stress-induced apoptosis in podocytes |
| Q50063006 | Guidelines for treatment of renal injury during cancer chemotherapy 2016. |
| Q58608502 | High intensity resistance training causes muscle damage and increases biomarkers of acute kidney injury in healthy individuals |
| Q36108356 | Hsp72 is an early and sensitive biomarker to detect acute kidney injury. |
| Q38797106 | Human kidney proximal tubule cells are vulnerable to the effects of Rauwolfia serpentina |
| Q35529004 | Hyperbaric oxygen therapy (HBOT) suppresses biomarkers of cell stress and kidney injury in diabetic mice |
| Q35740349 | Identification of Promising Urinary MicroRNA Biomarkers in Two Rat Models of Glomerular Injury |
| Q47234835 | Identification of aldo-keto reductase (AKR7A1) and glutathione S-transferase pi (GSTP1) as novel renal damage biomarkers following exposure to mercury |
| Q21089700 | Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity |
| Q41679816 | In vitro exposure of Adhatoda zeylanica to human renal cells lacks acute toxicity |
| Q42935646 | Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs |
| Q34928175 | Ischemic kidney injury and mechanisms of tissue repair |
| Q34453548 | Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media |
| Q30403111 | Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy |
| Q47386642 | Measuring non-polyaminated lipocalin-2 for cardiometabolic risk assessment |
| Q37803316 | Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development |
| Q38820393 | MicroRNAs and drug-induced kidney injury |
| Q92325495 | Molecular optical imaging probes for early diagnosis of drug-induced acute kidney injury |
| Q36017933 | Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling. |
| Q53100277 | Neutrophil Gelatinase-Associated Lipocalin as an Early Marker of Contrast-Induced Nephropathy After Elective Invasive Cardiac Procedures. |
| Q42738035 | New markers of acute kidney injury: giant leaps and baby steps |
| Q51151105 | Normal ranges and variability of novel urinary renal biomarkers in Sprague-Dawley Rats: comparison of constitutive values between males and females and across assay platforms. |
| Q36768728 | Performance of urinary and gene expression biomarkers in detecting the nephrotoxic effects of melamine and cyanuric acid following diverse scenarios of co-exposure |
| Q33901411 | Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study |
| Q47324570 | Personalized evaluation based on quantitative proteomics for drug-treated patients with chronic kidney disease |
| Q34305083 | Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals |
| Q46254914 | Preclinical biomarker qualification |
| Q37959015 | Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know |
| Q86067712 | Predicting long-term outcome in renal transplantation |
| Q55651995 | Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. |
| Q37921314 | Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification |
| Q35658669 | Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages |
| Q27024418 | Proteomics and metabolomics in renal transplantation-quo vadis? |
| Q36588385 | Public-private partnerships as driving forces in the quest for innovative medicines |
| Q39878923 | Rat Urinary Osteopontin and Neutrophil Gelatinase-Associated Lipocalin Improve Certainty of Detecting Drug-Induced Kidney Injury. |
| Q35506374 | Recent successes in the identification, development, and qualification of translational biomarkers: the next generation of kidney injury biomarkers |
| Q33799767 | Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases |
| Q21132990 | Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children |
| Q58071225 | Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium |
| Q57956749 | Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes |
| Q41502124 | Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies |
| Q35846103 | Role of biomarkers of nephrotoxic acute kidney injury in deliberate poisoning and envenomation in less developed countries |
| Q39995176 | STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies |
| Q38148980 | Safety biomarkers in preclinical development: translational potential |
| Q37351924 | Sex differences in kidney gene expression during the life cycle of F344 rats. |
| Q38638082 | Sweating the small stuff: Glycoproteins in human sweat and their unexplored potential for microbial adhesion |
| Q92109298 | Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women |
| Q38670777 | The CLU-files: disentanglement of a mystery |
| Q36391199 | The Utility of Gene Expression Profiling from Tissue Samples to Support Drug Safety Assessments |
| Q58765202 | The effect of remote ischemic preconditioning on serum creatinine in patients undergoing partial nephrectomy: a study protocol for a randomized controlled trial |
| Q64271334 | The predictive value of β2-MG and TGF-β for elderly hypertensive nephropathy |
| Q28572929 | Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats |
| Q58071230 | Towards consensus practices to qualify safety biomarkers for use in early drug development |
| Q33755928 | Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model |
| Q59563697 | Translational Biomarkers, In Vitro and In Vivo |
| Q55711027 | Urinary Cadmium Threshold to Prevent Kidney Disease Development. |
| Q60307291 | Urinary Proteomics in Biomarker Discovery of Kidney-Related Disorders: Diabetic Nephropathy and Drug-Induced Nephrotoxicity in Chronic Headache |
| Q42755579 | Urinary biomarkers in hexachloro-1:3-butadiene-induced acute kidney injury in the female Hanover Wistar rat; correlation of α-glutathione S-transferase, albumin and kidney injury molecule-1 with histopathology and gene expression |
| Q42220278 | Urinary biomarkers of acute kidney injury in deceased organ donors--kidney injury molecule-1 as an adjunct to predicting outcome |
| Q40964596 | Urinary biomarkers of chronic allograft nephropathy. |
| Q36770327 | Urinary cystatin C and acute kidney injury after cardiac surgery |
| Q53340836 | Urinary cystatin C levels as a diagnostic and prognostic biomarker in patients with acute kidney injury. |
| Q42703800 | Urinary excretion pattern of exosomal aquaporin-2 in rats that received gentamicin |
| Q34332083 | Urinary exosomes: a novel means to non-invasively assess changes in renal gene and protein expression |
| Q33887958 | Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development |
| Q37869464 | Urinary proteomics in cardiovascular disease: Achievements, limits and hopes |
| Q48244006 | Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus |
| Q36614166 | Urine free light chains as a novel biomarker of acute kidney allograft injury |
| Q52572915 | Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective. |
| Q35524711 | Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial |
| Q34906588 | Variation of nephrotoxicity biomarkers by urinary storage condition in rats |
Search more.